

Marta Boffito

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3455063/publications.pdf>

Version: 2024-02-01

103
papers

2,880
citations

218677

26
h-index

206112

48
g-index

109
all docs

109
docs citations

109
times ranked

3810
citing authors

#	ARTICLE	IF	CITATIONS
1	Strengths and Challenges of Various Models of Geriatric Consultation for Older Adults Living With Human Immunodeficiency Virus. <i>Clinical Infectious Diseases</i> , 2022, 74, 1101-1106.	5.8	14
2	Evaluation of a Clinic Dedicated to People Aging with HIV at Chelsea and Westminster Hospital: Results of a 10-Year Experience. <i>AIDS Research and Human Retroviruses</i> , 2022, 38, 188-197.	1.1	23
3	UK guideline for the use of HIV post-exposure prophylaxis 2021. <i>HIV Medicine</i> , 2022, 23, 494-545.	2.2	10
4	Prescribing Nirmatrelvir/Ritonavir: How to Recognize and Manage Drug-Drug Interactions. <i>Annals of Internal Medicine</i> , 2022, 175, 744-746.	3.9	35
5	Delivering specialised care to people ageing with HIV in the UK: experience and evolution of services from 2009 to 2019. <i>Lancet HIV</i> , 2022, 9, S1.	4.7	2
6	Editorial: Is it time to implement injectable antiretroviral treatments globally?. <i>Current Opinion in HIV and AIDS</i> , 2022, 17, 119-120.	3.8	0
7	Prevalence, severity, and risk factors of disability among adults living with HIV accessing routine outpatient HIV care in London, United Kingdom (UK): A cross-sectional self-report study. <i>PLoS ONE</i> , 2022, 17, e0267271.	2.5	1
8	Recommendations for the Management of Drug-Drug Interactions Between the COVID-19 Antiviral Nirmatrelvir/Ritonavir (Paxlovid) and Comedications. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 112, 1191-1200.	4.7	122
9	Toward Consensus on Correct Interpretation of Protein Binding in Plasma and Other Biological Matrices for COVID-19 Therapeutic Development. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 64-68.	4.7	21
10	Dose prediction for repurposing nitazoxanide in SARS-CoV-2 treatment or chemoprophylaxis. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 2078-2088.	2.4	46
11	Indirect Human Immunodeficiency Virus Morbidity and Mortality Due to Coronavirus Disease 2019. <i>Clinical Infectious Diseases</i> , 2021, 73, 1947-1949.	5.8	2
12	The evidence for using tenofovir disoproxil fumarate plus lamivudine as a nucleoside analogue backbone for the treatment of HIV. <i>Journal of Virus Eradication</i> , 2021, 7, 100028.	0.5	6
13	Feasibility randomized-controlled trial of online acceptance and commitment therapy for painful peripheral neuropathy in people living with HIV: The OPEN study. <i>European Journal of Pain</i> , 2021, 25, 1493-1507.	2.8	14
14	Remdesivir Versus Standard-of-Care for Severe Coronavirus Disease 2019 Infection: An Analysis of 28-Day Mortality. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab278.	0.9	31
15	Pharmacokinetic/pharmacodynamic investigation of raltegravir with or without lamivudine in the context of HIV-1 pre-exposure prophylaxis (PrEP). <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 2129-2136.	3.0	10
16	Factors associated with overweight/obesity in a cohort of people living with HIV over 50 years of age. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2021, , 1-3.	1.2	10
17	Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine. <i>New England Journal of Medicine</i> , 2021, 385, 1172-1183.	27.0	734
18	Current Considerations for Clinical Management and Care of People with HIV: Findings from the 11th Annual International HIV and Aging Workshop. <i>AIDS Research and Human Retroviruses</i> , 2021, 37, 807-820.	1.1	1

#	ARTICLE	IF	CITATIONS
19	More evidence for worse COVID-19 outcomes in people with HIV. <i>Lancet HIV</i> ,the, 2021, 8, e661-e662.	4.7	10
20	Predictive value of HIV-related versus traditional risk factors for coronary atherosclerosis in people aging with HIV. <i>AIDS Research and Human Retroviruses</i> , 2021, , .	1.1	2
21	Weight gain stopping/switch rules for antiretroviral clinical trials. <i>Aids</i> , 2021, 35, S183-S188.	2.2	15
22	Pharmacokinetic interactions of modern antiretroviral therapy. <i>Aids</i> , 2021, 35, S145-S151.	2.2	5
23	Use of Coronary Artery Calcium Scoring to Improve Cardiovascular Risk Stratification and Guide Decisions to Start Statin Therapy in People Living With HIV. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2020, 85, 98-105.	2.1	12
24	Incidental findings in elderly people living with HIV undergoing computed tomography coronary artery calcium scoring. <i>Aids</i> , 2020, 34, 1573-1575.	2.2	0
25	Associations Between Widespread Pain and Sleep Quality in People With HIV. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2020, 85, 106-112.	2.1	15
26	The predictors of pain extent in people living with HIV. <i>Aids</i> , 2020, 34, 2071-2079.	2.2	9
27	Comorbidity indices in people with HIV and considerations for coronavirus disease 2019 outcomes. <i>Aids</i> , 2020, 34, 1795-1800.	2.2	7
28	Rapid ART start in early HIV infection: Time to viral load suppression and retention in care in a London cohort. <i>HIV Medicine</i> , 2020, 21, 613-615.	2.2	6
29	Multimodality assessment of sleep outcomes in people living with HIV performed using validated sleep questionnaires. <i>International Journal of STD and AIDS</i> , 2020, 31, 996-1003.	1.1	13
30	COVID-19 in patients with HIV. <i>Lancet HIV</i> ,the, 2020, 7, e383.	4.7	19
31	Changes in functional connectivity in people with HIV switching antiretroviral therapy. <i>Journal of NeuroVirology</i> , 2020, 26, 754-763.	2.1	9
32	Clinical management of ageing people living with HIV in Europe: the view of the care providers. <i>Infection</i> , 2020, 48, 497-506.	4.7	7
33	Antiretroviral resistance and management after pre-exposure prophylaxis. <i>Lancet HIV</i> ,the, 2020, 7, e84.	4.7	9
34	Genetic influence of ABCG2, UGT1A1 and NR1I2 on dolutegravir plasma pharmacokinetics. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 1259-1266.	3.0	6
35	Increased Dolutegravir Peak Concentrations in People Living With Human Immunodeficiency Virus Aged 60 and Over, and Analysis of Sleep Quality and Cognition. <i>Clinical Infectious Diseases</i> , 2019, 68, 87-95.	5.8	49
36	Pharmacokinetics of Efavirenz 400 mg Once Daily Coadministered With Isoniazid and Rifampicin in Human Immunodeficiency Virusâ€“Infected Individuals. <i>Clinical Infectious Diseases</i> , 2019, 68, 446-452.	5.8	21

#	ARTICLE	IF	CITATIONS
37	Pharmacokinetics (PK) of ethinylestradiol/levonorgestrel co-administered with atazanavir/cobicistat. HIV Research and Clinical Practice, 2019, 20, 82-91.	1.1	0
38	Evaluation of the psychometric properties of the HIV Disability Questionnaire among adults living with HIV in the United Kingdom: A cross-sectional self-report measurement study. PLoS ONE, 2019, 14, e0213222.	2.5	22
39	Inclusion of pregnant women in antiretroviral drug research: what is needed to move forwards?. Journal of the International AIDS Society, 2019, 22, e25372.	3.0	15
40	Pharmacological impact of antiretroviral therapy on platelet function to investigate human immunodeficiency virus-associated cardiovascular risk. British Journal of Pharmacology, 2019, 176, 879-889.	5.4	24
41	Quantification of tenofovir disoproxil fumarate and emtricitabine in generic pre-exposure prophylaxis tablets obtained from the internet. International Journal of STD and AIDS, 2019, 30, 765-768.	1.1	4
42	Pharmacokinetics of dolutegravir 100 mg once daily with rifampicin. International Journal of Antimicrobial Agents, 2019, 54, 202-206.	2.5	31
43	Guidelines in the context of medical ethics. BMJ: British Medical Journal, 2019, 364, l1040.	2.3	0
44	Rifampicin effect on intracellular and plasma pharmacokinetics of tenofovir alafenamide. Journal of Antimicrobial Chemotherapy, 2019, 74, 1670-1678.	3.0	42
45	A Lower Dose of Efavirenz Can Be Coadministered With Rifampicin and Isoniazid in Tuberculosis Patients. Open Forum Infectious Diseases, 2019, 6, ofz035.	0.9	5
46	Pharmacokinetics of dolutegravir with and without darunavir/cobicistat in healthy volunteers. Journal of Antimicrobial Chemotherapy, 2019, 74, 149-156.	3.0	8
47	Characterization of low level viraemia in HIV-infected patients receiving boosted protease inhibitor-based antiretroviral regimens. HIV Research and Clinical Practice, 2019, 20, 107-110.	1.1	2
48	Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics of Efavirenz 400 mg Once Daily During Pregnancy and Post-Partum. Clinical Infectious Diseases, 2018, 67, 785-790.	5.8	25
49	Measurement of Retinal Vessels as a Biomarker of Cerebrovascular Aging in Older HIV-Positive Men Compared With Controls. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 77, 199-205.	2.1	7
50	Pharmacokinetics and pharmacodynamics of the nucleoside sparing dual regimen containing rilpivirine plus darunavir/ritonavir in treatment-naïve HIV-1-infected individuals. HIV Clinical Trials, 2018, 19, 31-37.	2.0	2
51	Pain in people living with HIV and its association with healthcare resource use, well being and functional status. Aids, 2018, 32, 2697-2706.	2.2	47
52	Rilpivirine long-acting for the prevention and treatment of HIV infection. Current Opinion in HIV and AIDS, 2018, 13, 300-307.	3.8	26
53	Cohort profile: The Pharmacokinetic and clinical Observations in PeoPle over fiftY (POPPY) study. International Journal of Epidemiology, 2018, 47, 1391-1392e.	1.9	33
54	An Open-Label, Randomized Study of the Impact on Insulin Sensitivity, Lipid Profile and Vascular Inflammation by Treatment with Lopinavir/Ritonavir or Raltegravir in HIV-Negative Male Volunteers. Antiviral Therapy, 2017, 22, 145-151.	1.0	6

#	ARTICLE	IF	CITATIONS
55	Once-daily atazanavir/cobicistat and darunavir/cobicistat exposure over 72 h post-dose in plasma, urine and saliva: contribution to drug pharmacokinetic knowledge. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 2035-2041.	3.0	6
56	Antiviral Activity, Safety, and Exposure-Response Relationships of GSK3532795, a Second-Generation Human Immunodeficiency Virus Type 1 Maturation Inhibitor, Administered as Monotherapy or in Combination With Atazanavir With or Without Ritonavir in a Phase 2a Randomized, Dose-Ranging, Controlled Trial (A1468002). <i>Clinical Infectious Diseases</i> , 2017, 65, 442-452.	5.8	18
57	The triumph of HIV treatment: another new antiretroviral. <i>Lancet</i> , The, 2017, 390, 2019-2021.	13.7	6
58	Long-acting cabotegravir for prevention: hope versus reality. <i>Lancet HIV</i> , 2017, 4, e322-e323.	4.7	4
59	O015...Establishment of a monitoring service for men who have sex with men (MSM) taking generic co-formulated tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC) as pre-exposure prophylaxis (PrEP) against HIV infection. <i>Sexually Transmitted Infections</i> , 2016, 92, A6.1-A6.	1.9	0
60	Development, Validation, and Field-Testing of an Instrument for Clinical Assessment of HIV-Associated Neuropathy and Neuropathic Pain in Resource-Restricted and Large Population Study Settings. <i>PLoS ONE</i> , 2016, 11, e0164994.	2.5	27
61	The pharmacokinetics of high-dose methotrexate in people living with HIV on antiretroviral therapy. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 77, 653-657.	2.3	5
62	British HIV Association guidelines for the treatment of HIV-positive adults with antiretroviral therapy 2015. <i>HIV Medicine</i> , 2016, 17, s2-s104.	2.2	78
63	Iatrogenic Cushing's syndrome due to drug interaction between glucocorticoids and the ritonavir or cobicistat containing HIV therapies. <i>Clinical Medicine</i> , 2016, 16, 412-418.	1.9	36
64	The development and application of a novel LC-MS/MS method for the measurement of Dolutegravir, Elvitegravir and Cobicistat in human plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2016, 1027, 174-180.	2.3	29
65	Selection of Rilpivirine-Resistant HIV-1 in a Seroconverter From the SSAT 040 Trial Who Received the 300-mg Dose of Long-Acting Rilpivirine (TMC278LA). <i>Journal of Infectious Diseases</i> , 2016, 213, 1013-1017.	4.0	40
66	Dolutegravir and elvitegravir plasma concentrations following cessation of drug intake. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1031-1036.	3.0	29
67	Simulation of the impact of rifampicin on once-daily darunavir/ritonavir pharmacokinetics and dose adjustment strategies: a population pharmacokinetic approach. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1041-1045.	3.0	5
68	Twenty years of boosting antiretroviral agents. <i>Aids</i> , 2015, 29, 2229-2233.	2.2	9
69	Effect of a Modified Saquinavir/Ritonavir Dosing Regimen with Lower Dose Lead-In Phase on QTc Interval, Pharmacokinetics, Antiviral Activity and Safety in Treatment-Naïve HIV-1-Infected Patients. <i>Drugs in R and D</i> , 2015, 15, 141-153.	2.2	5
70	Unexpected rapid weight gain in a patient with HIV and anorexia. <i>BMJ</i> , The, 2015, 351, h5551.	6.0	0
71	Should the dose of tenofovir be reduced to 200-250 mg/day, when combined with protease inhibitors?. <i>Journal of the International AIDS Society</i> , 2014, 17, 19583.	3.0	14
72	Effect of hyperbilirubinaemia on neurocognitive, renal, bone and cardiovascular markers in HIV infection treated with boosted protease inhibitors. <i>Journal of the International AIDS Society</i> , 2014, 17, 19827.	3.0	1

#	ARTICLE	IF	CITATIONS
73	Simulation of the impact of rifampicin on darunavir/ritonavir PK and dose adjustment strategies in HIV-infected patients: a population PK approach. <i>Journal of the International AIDS Society</i> , 2014, 17, 19586.	3.0	4
74	Transmitted antiretroviral drug resistance in treatment naïve HIV-infected persons in London in 2011 to 2013. <i>Journal of the International AIDS Society</i> , 2014, 17, 19747.	3.0	4
75	Pharmacology Lessons From Chemoprophylaxis Studies. <i>Clinical Infectious Diseases</i> , 2014, 59, S52-S54.	5.8	4
76	Pharmacokinetics of the co-administration of boceprevir and St John's wort to male and female healthy volunteers. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 1911-1915.	3.0	13
77	New Approaches to Antiretroviral Drug Delivery: Challenges and Opportunities Associated with the Use of Long-Acting Injectable Agents. <i>Drugs</i> , 2014, 74, 7-13.	10.9	35
78	Safety, immunogenicity and efficacy assessment of HIV immunotherapy in a multi-centre, double-blind, randomised, Placebo-controlled Phase Ib human trial. <i>Vaccine</i> , 2013, 31, 5680-5686.	3.8	18
79	Pharmacokinetics of Once-Daily Darunavir-Ritonavir and Atazanavir-Ritonavir over 72 Hours following Drug Cessation. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 4218-4223.	3.2	35
80	Pharmacokinetics and Safety of Etravirine Administered Once or Twice Daily After 2 Weeks Treatment With Efavirenz in Healthy Volunteers. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009, 52, 222-227.	2.1	28
81	Pharmacokinetics, Efficacy, and Safety of Darunavir/Ritonavir 800/100 mg Once-Daily in Treatment-Naïve and -Experienced Patients. <i>HIV Clinical Trials</i> , 2008, 9, 418-427.	2.0	80
82	Pharmacokinetics of atazanavir/ritonavir once daily and lopinavir/ritonavir twice and once daily over 72 h following drug cessation. <i>Antiviral Therapy</i> , 2008, 13, 901-7.	1.0	14
83	Pharmacokinetics of Atazanavir/Ritonavir Once Daily and Lopinavir/Ritonavir Twice and once Daily over 72 h following drug Cessation. <i>Antiviral Therapy</i> , 2008, 13, 901-907.	1.0	32
84	Pharmacology of Current and Investigational Human Immunodeficiency virus (HIV) Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Adults. <i>Anti-Infective Agents in Medicinal Chemistry</i> , 2007, 6, 213-221.	0.6	2
85	Pharmacokinetics and antiretroviral response to darunavir/ritonavir and etravirine combination in patients with high-level viral resistance. <i>Aids</i> , 2007, 21, 1449-1455.	2.2	70
86	Pharmacokinetics and pharmacodynamics in HAART and antibiotic therapy. <i>New Microbiologica</i> , 2007, 30, 346-9.	0.1	0
87	Abacavir Plasma Pharmacokinetics in the Absence and Presence of Atazanavir/Ritonavir or Lopinavir/Ritonavir and Vice Versa in HIV-Infected Patients. <i>Antiviral Therapy</i> , 2007, 12, 825-830.	1.0	28
88	Pharmacokinetics of Saquinavir Hard-Gel/Ritonavir and Atazanavir When Combined Once Daily in HIV Type 1-Infected Individuals Administered Different Atazanavir Doses. <i>AIDS Research and Human Retroviruses</i> , 2006, 22, 749-756.	1.1	21
89	Practical Perspectives on the Use of Tipranavir in Combination With Other Medications: Lessons Learned From Pharmacokinetic Studies. <i>Journal of Clinical Pharmacology</i> , 2006, 46, 130-139.	2.0	17
90	Host determinants of antiretroviral drug activity. <i>Current Opinion in Infectious Diseases</i> , 2005, 18, 543-549.	3.1	13

#	ARTICLE	IF	CITATIONS
91	The pharmacokinetics of HIV protease inhibitor combinations. <i>Current Opinion in Infectious Diseases</i> , 2005, 18, 1-7.	3.1	35
92	Pharmacokinetics of saquinavir hard gel/ritonavir (1000/100 mg twice daily) when administered with tenofovir diproxil fumarate in HIV-1-infected subjects. <i>British Journal of Clinical Pharmacology</i> , 2005, 59, 38-42.	2.4	17
93	Lack of Pharmacokinetic Drug Interaction between Tenofovir Disoproxil Fumarate and Nelfinavir Mesylate. <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 4386-4389.	3.2	24
94	Boosted saquinavir hard gel formulation exposure in HIV-infected subjects: ritonavir 100%mg once daily versus twice daily. <i>Journal of Antimicrobial Chemotherapy</i> , 2005, 55, 542-545.	3.0	10
95	Current status and future prospects of therapeutic drug monitoring and applied clinical pharmacology in antiretroviral therapy. <i>Antiviral Therapy</i> , 2005, 10, 375-92.	1.0	13
96	Therapeutic drug monitoring and drug-drug interactions involving antiretroviral drugs. <i>Antiviral Therapy</i> , 2005, 10, 469-77.	1.0	16
97	Steady-State Pharmacokinetics of Saquinavir Hard-Gel/Ritonavir/Fosamprenavir in HIV-1-Infected Patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2004, 37, 1376-1384.	2.1	28
98	Atazanavir enhances saquinavir hard-gel concentrations in a ritonavir-boosted once-daily regimen. <i>Aids</i> , 2004, 18, 1291-1297.	2.2	62
99	Pharmacokinetic considerations for combining 2 protease inhibitors. <i>Aids Reader</i> , 2004, 14, 110-2, 115-6.	0.3	6
100	Can we boost enough without ritonavir?. <i>Aids Reader</i> , 2004, 14, 229-30, 233-5.	0.3	2
101	Pharmacokinetics of once-daily saquinavir/ritonavir in HIV-infected subjects: comparison with the standard twice-daily regimen. <i>Antiviral Therapy</i> , 2004, 9, 423-9.	1.0	5
102	Pharmacokinetics of Once-Daily Saquinavir/Ritonavir in HIV-Infected Subjects: Comparison with the Standard Twice-Daily Regimen. <i>Antiviral Therapy</i> , 2004, 9, 423-429.	1.0	26
103	Protein Binding in Antiretroviral Therapies. <i>AIDS Research and Human Retroviruses</i> , 2003, 19, 825-835.	1.1	173